Research Interests
Research Interests
Dr. Green’s Biomaterials and Drug Delivery Laboratory is interested in biomaterials, drug delivery, gene therapy, nanobiotechnology, and cell engineering. Research findings — and the technologies developed — are applied in the fields of ophthalmology, oncology, and regenerative medicine.
The lab works within the chemistry/biology/engineering interface to answer fundamental scientific questions, and to create innovative technologies and therapeutics that can directly benefit human health.
Current projects include:
- Development of safe and effective biodegradable nanoparticles for DNA and siRNA delivery to treat cancer
- Polymeric microparticle-based biological treatments for age-related macular degeneration
- Design of biomimetic artificial antigen presenting cells for immunoengineering
- Enabling technologies for tissue engineering and regenerative medicine
Titles & Affiliations
Titles
- Professor, Biomedical Engineering
- Director, Biomedical Engineering Undergraduate Program
- Professor, Ophthalmology
- Professor, Oncology
- Professor, Neurosurgery
- Professor, Materials Science & Engineering
- Professor, Chemical & Biomolecular Engineering
Affiliated Centers & Institutes
Education
Education
- PhD, Biological Engineering, Massachusetts Institute of Technology, 2007
- BS, Chemical Engineering, Biomedical Engineering, Carnegie Mellon University, 2003
Faculty News
Recent Highlights
-
January 6, 2022Johns Hopkins Medicine researchers have developed a color-coded test that quickly signals whether newly developed nanoparticles deliver their cargo into target cells.
-
December 20, 2021Jordan Green has been elected a Fellow of the National Academy of Inventors, a distinction that honors academic inventors who have created or facilitated outstanding inventions that have had an impact on society.
-
July 9, 2020In experiments in rats and mice, two Johns Hopkins scientists — an engineer and an ophthalmologist — report the successful use of nanoparticles to deliver gene therapy for blinding eye disease.
Media